Search results for "Coronavirus"
Telemedicine tips for internists in the era of COVID-19
Optimizing your telemedicine practice, or even starting it as part of your response to the COVID-19 pandemic, doesn't have to be a frantic process.
https://immattersacp.org/archives/2020/05/telemedicine-tips-for-internists-in-the-era-of-covid-19.htm
1 May 2020
Latest COVID-19 research on VTE risk, treatment with metformin, ivermectin, fluvoxamine
Unvaccinated patients may have higher risk of venous thromboembolism (VTE) when mildly ill, one study found, while another showed no effect from metformin, ivermectin, or fluvoxamine. Research supported the safety of the mRNA vaccines, and the NIH updated its treatment guidelines.
https://immattersacp.org/weekly/archives/2022/08/23/4.htm
23 Aug 2022
We must rise with the occasion and save our country
The current COVID-19 pandemic requires that ACP carefully craft public policies not only for how care is organized and delivered on the front lines but also for helping physicians save patients while keeping themselves safe as well.
https://immattersacp.org/archives/2020/05/we-must-rise-with-the-occasion-and-save-our-country.htm
1 May 2020
IDSA offers guidance on managing drug interactions with nirmatrelvir/ritonavir
The Infectious Diseases Society of America (IDSA) listed six steps to help clinicians prescribe the COVID-19 medication while minimizing interaction risks. Other recent research looked at neuropsychiatric conditions after COVID-19 and hospital profits during the pandemic.
https://immattersacp.org/weekly/archives/2022/05/17/2.htm
17 May 2022
Oral medications for COVID-19 underused among socially vulnerable, CDC study finds
By late May, the rate of prescriptions for molnupiravir and nirmatrelvir/ritonavir was twice as high in the highest-income U.S. ZIP codes as in the lowest, research showed. A CDC webinar on June 28 will discuss efforts to equitably distribute these treatments.
https://immattersacp.org/weekly/archives/2022/06/28/2.htm
28 Jun 2022
Nirmatrelvir/ritonavir rarely leads to rebound, doesn't help average-risk patients, studies find
A retrospective analysis found that symptom rebound occurred in less than 1% of high-risk COVID-19 patients treated with nirmatrelvir/ritonavir, while the manufacturer reported that the drug didn't show significant benefit in average-risk patients.
https://immattersacp.org/weekly/archives/2022/06/21/2.htm
21 Jun 2022
Boosters, antithrombotic therapy, mental health effects, more COVID-19 news
FDA advisors recommended booster administration for the Moderna vaccine for certain populations, an ACP/Annals forum covered the immunology of SARS-CoV-2, a trial showed that neither aspirin nor apixaban benefited outpatients with COVID-19, and ACP partnered with YouTube to combat medical misinformation related to COVID-19.
https://immattersacp.org/weekly/archives/2021/10/19/2.htm
19 Oct 2021
Fourth vaccine dose 62% effective against severe COVID-19 in month after receipt
Retrospective data from Israel showed that in people ages 60 years and older, an additional booster dose of the Pfizer-BioNTech COVID-19 vaccine was 55% effective against symptomatic disease and 68% effective against hospitalization.
https://immattersacp.org/weekly/archives/2022/04/19/4.htm
19 Apr 2022
Studies examine persistent symptoms of COVID-19
A U.K. study found that COVID-19 vaccination after infection may help persistent symptoms, while a U.S. study found that the burden of such symptoms appears high.
https://immattersacp.org/weekly/archives/2022/05/24/5.htm
24 May 2022
Register now for ACP and Annals of Internal Medicine's COVID-19 Forum VIII: Outpatient Evaluation and Management of Patients with COVID-19
During the Feb. 9 virtual live event, a panel of experts will discuss appropriate COVID-19 testing, quarantine and isolation periods, management of symptoms, and recommended treatments in the outpatient setting.
https://immattersacp.org/weekly/archives/2022/02/01/2.htm
1 Feb 2022